AU · rank #5 · 2026-06-03
CORT
NASDAQ · $7.15B
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.144 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.89 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.099 |
| Analyst upside Consensus target $79.00 | +11.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +108.56% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $91.00 |
| Market cap | $7.15B |
The AI research card
Independent qualitative review of each pick before the order is placed.
Summary
Corcept is a commercial-stage biotech with marketed Korlym (mifepristone) for Cushing's syndrome and a late-stage pipeline of selective cortisol modulators (relacorilant, miricorilant) across multiple indications.
Rationale
Strong 10.96% analyst upside, 4.5/5 rating, and 108.6% momentum acceleration align with Q1 2026 beat (+47% YoY revenue), raised FY2026 guidance, and positive Phase 2 miricorilant data, supported by fortress balance sheet ($624.5M cash, no debt) enabling self-funded pipeline advancement.
Material risks
- 1Regulatory/legal risk around Korlym including potential FDA label restrictions, safety warnings, or litigation settlements that could materially constrain promotion and revenue trajectory in the core franchise.
- 2Phase 3 clinical failure risk—GRACE trial top-line data (H1 2027) is critical to relacorilant's value thesis; negative results would undermine the pipeline growth narrative and analyst upside assumptions.
Verdict reasoning
two_stage score=+3/3 verdicts={'gemini': 'PROCEED', 'openai': 'PROCEED', 'claude': 'PROCEED'} brief=caller-supplied